Apart from ibrutinib, patients with M-CLL, devoid of TP53 aberrations and fit plenty of to tolerate FCR therapy, may still be fantastic candidates to the latter, With all the gain getting that this cure might be completed in 6 months while ibrutinib need to be taken indefinitely. This option will be particularly worthwhile for non-compliant patient… Read More